Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Banna, Giuseppe Luigi; Addeo, Alfredo

doi:10.1056/NEJMc2411471

Scientific article

Comment

English

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

ContributorsBanna, Giuseppe Luigi; Addeo, Alfredo

Published inThe New England journal of medicine, vol. 391, no. 16, p. 1555

Publication date2024-10-24

Abstract

Comment on : Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. PMID: 38828946.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Citation (ISO format)

BANNA, Giuseppe Luigi, ADDEO, Alfredo. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC. In: The New England journal of medicine, 2024, vol. 391, n° 16, p. 1555. doi: 10.1056/NEJMc2411471

Article (Published version)

Identifiers

PID : unige:183988
DOI : 10.1056/NEJMc2411471
PMID : 39442049

Additional URL for this publicationhttp://www.nejm.org/doi/10.1056/NEJMc2411471

Journal ISSN0028-4793

18views

0downloads

Creation25/02/2025 09:38:37

First validation20/03/2025 09:21:04

Update20/03/2025 09:21:04

Status update20/03/2025 09:21:04

Last indexation20/03/2025 09:21:05

Archive ouverte UNIGE

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

Technical informations